EURETINA 2021 Virtual Sponsors

Sponsors

Alcon Management SA

Alcon

Alimera Sciences

Alimera Sciences is a pharmaceutical company that specialises in the commercialisation and development of prescription ophthalmic pharmaceuticals. It was founded in 2003 and is currently focused on diseases affecting the posterior segment of the eye. For more information, please visit www.alimerasciences.eu

Alimera Sciences

Alimera Sciences is a pharmaceutical company that specialises in the commercialisation and development of prescription ophthalmic pharmaceuticals. It was founded in 2003 and is currently focused on diseases affecting the posterior segment of the eye. For more information, please visit www.alimerasciences.eu

Allergan

About AbbVie AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com/. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn. About Allergan Eye Care As a leader in eye care, Allergan has discovered, developed, and delivered some of the most innovative products in the industry for more than 70 years. Allergan has launched over 125 eye care products and invested billions of dollars in new treatments for the most prevalent eye conditions, including glaucoma, ocular surface disease, and retinal diseases such as diabetic macular edema and retinal vein occlusion.

Allergan

About AbbVie AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com/. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn. About Allergan Eye Care As a leader in eye care, Allergan has discovered, developed, and delivered some of the most innovative products in the industry for more than 70 years. Allergan has launched over 125 eye care products and invested billions of dollars in new treatments for the most prevalent eye conditions, including glaucoma, ocular surface disease, and retinal diseases such as diabetic macular edema and retinal vein occlusion.

Amgen

Amgen

Apellis Switzerland GmbH

Apellis is a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing medicines. As leaders in research of targeted C3 therapies, we aim to develop new therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, nephrology, neurology and ophthalmology with focus on Geographic Atrophy. We have designed a complement inhibitor to target complement proteins centrally at the level of C3. We believe that this approach can regulate uncontrolled or excessive complement activation that occurs in several debilitating diseases as in Geographic Atrophy.

Apellis Switzerland GmbH

Apellis is a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing medicines. As leaders in research of targeted C3 therapies, we aim to develop new therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, nephrology, neurology and ophthalmology with focus on Geographic Atrophy. We have designed a complement inhibitor to target complement proteins centrally at the level of C3. We believe that this approach can regulate uncontrolled or excessive complement activation that occurs in several debilitating diseases as in Geographic Atrophy.

Bausch + Lomb

With over 168 years of innovation, Bausch+Lomb is a leading global eye care brand with expertise in contact lenses and lens care, pharmaceuticals and surgery. The Surgical Division provides a complete product portfolio for cataract, refractive, corneal and retinal surgery. This includes our combined Stellaris Elite™ system, designed to deliver optimized control and efficiency to a wide range for cataract and retinal procedures, the BiBlade® vitrectomy cutter with its dual port design and our Vitesse® hypersonic vitrectomy system for a new approach to vitreous removal. Combined with our comprehensive instrument range, we provide for individual surgeon techniques and patient needs.

Bausch + Lomb

With over 168 years of innovation, Bausch+Lomb is a leading global eye care brand with expertise in contact lenses and lens care, pharmaceuticals and surgery. The Surgical Division provides a complete product portfolio for cataract, refractive, corneal and retinal surgery. This includes our combined Stellaris Elite™ system, designed to deliver optimized control and efficiency to a wide range for cataract and retinal procedures, the BiBlade® vitrectomy cutter with its dual port design and our Vitesse® hypersonic vitrectomy system for a new approach to vitreous removal. Combined with our comprehensive instrument range, we provide for individual surgeon techniques and patient needs.

Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros.

Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros.

BVI

BVI® is refocusing the future of vision.   With a diversified and purpose-built portfolio spanning more than 115 countries, we touch the lives of millions of patients affected by conditions such as cataracts, refractive error, glaucoma, and retinal disease.   Unburdened by legacy, we have developed our strategy around a simple concept — taking pride in delivering innovative solutions to meet the needs of our physicians and patients. We trust and empower our associates to make decisions and solve problems.  Valuing agility, simplicity, and transparency, we stay committed to listening to our customers, delivering for our patients, and keeping the future in focus. 

BVI

BVI® is refocusing the future of vision.   With a diversified and purpose-built portfolio spanning more than 115 countries, we touch the lives of millions of patients affected by conditions such as cataracts, refractive error, glaucoma, and retinal disease.   Unburdened by legacy, we have developed our strategy around a simple concept — taking pride in delivering innovative solutions to meet the needs of our physicians and patients. We trust and empower our associates to make decisions and solve problems.  Valuing agility, simplicity, and transparency, we stay committed to listening to our customers, delivering for our patients, and keeping the future in focus. 

Biogen

At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases. Biogen has a portfolio of medicines to treat certain types of multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, commercializes biosimilars, and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute neurology.

Biogen

At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases. Biogen has a portfolio of medicines to treat certain types of multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, commercializes biosimilars, and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute neurology.

Zeiss

Carl Zeiss Meditec AG offers complete solutions, including implants and consumables, to diagnose and treat eye conditions and ophthalmic diseases. The comprehensive ZEISS portfolio is designed to meet the demands of eye care professionals and help them deal with an increasingly challenging healthcare environment.

Zeiss

Carl Zeiss Meditec AG offers complete solutions, including implants and consumables, to diagnose and treat eye conditions and ophthalmic diseases. The comprehensive ZEISS portfolio is designed to meet the demands of eye care professionals and help them deal with an increasingly challenging healthcare environment.

FCI S.A.S.

FCI S.A.S. is a world leader in the development of a wide range of ophthalmic devices. Since the company’s inception in 1984, FCI has been dedicated to provide physicians with innovative, high-performance and mostly exclusive products covering the fields of expertise of Oculoplasty, Dry Eye, Retina and Cataract. FCI is a global, multi-site company with its headquarter in Paris, France, a branch FCI Ophthalmics in Boston, MA (USA) managing our North American operations, and a strong distribution network that serves more than 80 countries. Our core business and activities involve extensive research & development and advanced manufacturing processes to enhance the effectiveness and performance of the procedures performed by our customers. Your Patients, Our Expertise.

FCI S.A.S.

FCI S.A.S. is a world leader in the development of a wide range of ophthalmic devices. Since the company’s inception in 1984, FCI has been dedicated to provide physicians with innovative, high-performance and mostly exclusive products covering the fields of expertise of Oculoplasty, Dry Eye, Retina and Cataract. FCI is a global, multi-site company with its headquarter in Paris, France, a branch FCI Ophthalmics in Boston, MA (USA) managing our North American operations, and a strong distribution network that serves more than 80 countries. Our core business and activities involve extensive research & development and advanced manufacturing processes to enhance the effectiveness and performance of the procedures performed by our customers. Your Patients, Our Expertise.

Heidelberg Engineering GmbH

Heidelberg Engineering continuously optimizes imaging and healthcare IT technologies to provide ophthalmic diagnostic solutions that empower clinicians to improve patient care. From its inception in 1990, the company has collaborated with scientists, clinicians and industry to develop innovative products that deliver clinically relevant benefits. Uncompromising quality and education play a large part in fostering the diagnostic confidence that has become synonymous with the global brand. The growing product portfolio combines these core technologies: confocal microscopy, scanning lasers and optics, optical coherence tomography (OCT), real-time image processing and analytics, multimodal image management solutions (PACS), electronic medical records (EMR), large-scale data analysis.

Heidelberg Engineering GmbH

Heidelberg Engineering continuously optimizes imaging and healthcare IT technologies to provide ophthalmic diagnostic solutions that empower clinicians to improve patient care. From its inception in 1990, the company has collaborated with scientists, clinicians and industry to develop innovative products that deliver clinically relevant benefits. Uncompromising quality and education play a large part in fostering the diagnostic confidence that has become synonymous with the global brand. The growing product portfolio combines these core technologies: confocal microscopy, scanning lasers and optics, optical coherence tomography (OCT), real-time image processing and analytics, multimodal image management solutions (PACS), electronic medical records (EMR), large-scale data analysis.

Horus PHARMA

Horus PHARMA

Iridex

Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the for treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Since 2015, more than 150,000 patients have been treated with Iridex’s MicroPulse® Transscleral Laser Therapy using the MicroPulse P3® Delivery Device. In 2020, the footplate of the MicroPulse P3 Delivery Device was enhanced to allow it to deliver greater stability, visualization, coupling, and fit. MicroPulse TLT is a non-incisional procedure that substantially reduces IOP for a broad range of glaucoma patients. The procedure can be used for primary open-angle, closed-angle, and refractory glaucoma. It can be performed before, in combination with, or after other glaucoma treatments, making it a very versatile tool.

IVERIC BIO

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. Vision is Our Mission. For more information on the Company, please visit www.ivericbio.com

Iridex

Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the for treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Since 2015, more than 150,000 patients have been treated with Iridex’s MicroPulse® Transscleral Laser Therapy using the MicroPulse P3® Delivery Device. In 2020, the footplate of the MicroPulse P3 Delivery Device was enhanced to allow it to deliver greater stability, visualization, coupling, and fit. MicroPulse TLT is a non-incisional procedure that substantially reduces IOP for a broad range of glaucoma patients. The procedure can be used for primary open-angle, closed-angle, and refractory glaucoma. It can be performed before, in combination with, or after other glaucoma treatments, making it a very versatile tool.

IVERIC BIO

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. Vision is Our Mission. For more information on the Company, please visit www.ivericbio.com

Janssen

Janssen Retina: Preserving and Restoring Vision At Janssen, we are translating our understanding of the biology underlying retinal diseases to develop needed therapies that preserve and enhance vision. Janssen’s clinical-stage portfolio includes leading product candidates for inherited retinal diseases x-linked retinitis pigmentosa and achromatopsia. Janssen is also expanding into more common eye diseases, including wet age-related macular degeneration, diabetic retinopathy and diabetic macular edema.

Janssen

Janssen Retina: Preserving and Restoring Vision At Janssen, we are translating our understanding of the biology underlying retinal diseases to develop needed therapies that preserve and enhance vision. Janssen’s clinical-stage portfolio includes leading product candidates for inherited retinal diseases x-linked retinitis pigmentosa and achromatopsia. Janssen is also expanding into more common eye diseases, including wet age-related macular degeneration, diabetic retinopathy and diabetic macular edema.

Karger Publishers

Karger Publishers, headquartered in Basel, Switzerland, is a globally active publishing house in Health Sciences. It is independent and family-run in the fourth generation with 240 employees worldwide. S. Karger AG consists of the publishing company Karger Publishers (est. 1890) and the International Subscription Agency Karger Libri (est. 1960). Chairwoman and Publisher Gabriella Karger leads the publishing company and S. Karger AG together with CEO Daniel Ebneter and COO Andre Janssen. In addition to the company headquarters in Basel, Switzerland there are subsidiaries and regional offices around the globe.

Karger Publishers

Karger Publishers, headquartered in Basel, Switzerland, is a globally active publishing house in Health Sciences. It is independent and family-run in the fourth generation with 240 employees worldwide. S. Karger AG consists of the publishing company Karger Publishers (est. 1890) and the International Subscription Agency Karger Libri (est. 1960). Chairwoman and Publisher Gabriella Karger leads the publishing company and S. Karger AG together with CEO Daniel Ebneter and COO Andre Janssen. In addition to the company headquarters in Basel, Switzerland there are subsidiaries and regional offices around the globe.

NIDEK CO., LTD

NIDEK provides a wide range of equipment for refraction, diagnosis, and treatment of vision disorders. NIDEK will mark its 50th anniversary on August 8, 2021 and renewed company logo. We will continue to aim at being a leading company in “Eye & Health Care”, providing service that help people all over the world to live a healthy comfortable life and being a company, whose existence serves a purpose. At EURETINA 2021, NIDEK is pleased to introduce our innovative products such as Mirante, Multimodal Imaging Platform OCT/SLO Combo. Please find NIDEK industry company page at EURETINA virtual.

NIDEK CO., LTD

NIDEK provides a wide range of equipment for refraction, diagnosis, and treatment of vision disorders. NIDEK will mark its 50th anniversary on August 8, 2021 and renewed company logo. We will continue to aim at being a leading company in “Eye & Health Care”, providing service that help people all over the world to live a healthy comfortable life and being a company, whose existence serves a purpose. At EURETINA 2021, NIDEK is pleased to introduce our innovative products such as Mirante, Multimodal Imaging Platform OCT/SLO Combo. Please find NIDEK industry company page at EURETINA virtual.

Novartis

At Novartis, our mission is to discover new ways to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. In ophthalmology, we develop and deliver life-changing medicines and therapies for diseases and conditions from front to back of the eye, enabled by data and transformative technologies. Our ophthalmic solutions reach more than 150M people per year, from premature infants to the elderly.

Novartis

At Novartis, our mission is to discover new ways to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. In ophthalmology, we develop and deliver life-changing medicines and therapies for diseases and conditions from front to back of the eye, enabled by data and transformative technologies. Our ophthalmic solutions reach more than 150M people per year, from premature infants to the elderly.

OCULUS Surgical

OCULUS Surgical take care of its exclusive circle of customers – ophthalmic surgeons. The product range of the SDI®/BIOM® system is constantly expanding, new high-quality lenses are being created, both reusable and disposable. Do you know the HD Disposable LenZ for the ZEISS system? You can benefit from the OCULUS quality even if you don’t use the BIOM® system. We have more solutions for you: get in touch.

OCULUS Surgical

OCULUS Surgical take care of its exclusive circle of customers – ophthalmic surgeons. The product range of the SDI®/BIOM® system is constantly expanding, new high-quality lenses are being created, both reusable and disposable. Do you know the HD Disposable LenZ for the ZEISS system? You can benefit from the OCULUS quality even if you don’t use the BIOM® system. We have more solutions for you: get in touch.

Oertli Instrumente AG

MAKING THE DIFFERENCE IN EYE SURGERY Oertli develops, manufactures and distributes surgical platforms, instruments and consumables with which surgeons and OR personnel can work easier, safer and more efficient and thus achieving better results for the patient. LATEST INNOVATIONS NEW: OS 4 – The next generation! The all-in-one platform received various new features such as the Power LED with 45% more light power, fully automated laser protection and much more. NEW: Faros with Power LED! The compact platform for vitreoretinal, glaucoma and cataract surgery is now also available with a higher light output thanks to the latest Power LED illumination.

Oertli Instrumente AG

MAKING THE DIFFERENCE IN EYE SURGERY Oertli develops, manufactures and distributes surgical platforms, instruments and consumables with which surgeons and OR personnel can work easier, safer and more efficient and thus achieving better results for the patient. LATEST INNOVATIONS NEW: OS 4 – The next generation! The all-in-one platform received various new features such as the Power LED with 45% more light power, fully automated laser protection and much more. NEW: Faros with Power LED! The compact platform for vitreoretinal, glaucoma and cataract surgery is now also available with a higher light output thanks to the latest Power LED illumination.

Optos

Optos produce ultra-widefield optomap® images of approximately 82% or 200◦of the retina, something no other device is capable of doing in a single capture. optomap provides a bigger picture and more clinical information which facilitates the early detection, management and effective treatment of disorders and diseases evidenced in the retina. Optos is committed to utilizing the latest technology to manufacture new products and software that support optomap as a standard of care therefore helping eyecare professionals around the world save sight and lives. Furthermore, the company continues to strengthen its clinical evidence and expand its disease indications to demonstrate the importance of imaging the entire retina.

Optos

Optos produce ultra-widefield optomap® images of approximately 82% or 200◦of the retina, something no other device is capable of doing in a single capture. optomap provides a bigger picture and more clinical information which facilitates the early detection, management and effective treatment of disorders and diseases evidenced in the retina. Optos is committed to utilizing the latest technology to manufacture new products and software that support optomap as a standard of care therefore helping eyecare professionals around the world save sight and lives. Furthermore, the company continues to strengthen its clinical evidence and expand its disease indications to demonstrate the importance of imaging the entire retina.

QUANTEL MEDICAL - ELLEX

Quantel Medical and Ellex, companies of the Lumibird Medical group, offer innovative solutions in ophthalmic lasers and ultrasound scanners . For more information come and visit our websites.

QUANTEL MEDICAL - ELLEX

Quantel Medical and Ellex, companies of the Lumibird Medical group, offer innovative solutions in ophthalmic lasers and ultrasound scanners . For more information come and visit our websites.

Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Samsara Vision

Samsara Vision

Thirona

Thirona is a fast-growing, internationally operating med-tech company specialised in the field of AI assisted medical image analysis for lung and eye diseases. Our solutions are actively used in clinical practice, screening, medical research, and pharmaceutical trials. At Euretina 2021 we are presenting an EXCLUSIVE PREVIEW of RetCAD 2.0 software to be launched in Autumn 2021. RetCAD 2.0 will be a class IIa medical device under the new Medical Device Regulation (MDR), which uses state of the art deep learning and computer vision technology to analyze color fundus images for screening of vision threatening diseases, including AMD, DR and Glaucoma.

Thirona

Thirona is a fast-growing, internationally operating med-tech company specialised in the field of AI assisted medical image analysis for lung and eye diseases. Our solutions are actively used in clinical practice, screening, medical research, and pharmaceutical trials. At Euretina 2021 we are presenting an EXCLUSIVE PREVIEW of RetCAD 2.0 software to be launched in Autumn 2021. RetCAD 2.0 will be a class IIa medical device under the new Medical Device Regulation (MDR), which uses state of the art deep learning and computer vision technology to analyze color fundus images for screening of vision threatening diseases, including AMD, DR and Glaucoma.

Topcon Healthcare

Topcon Healthcare

Register today

Registration for EURETINA 2021 Virtual is now open. Registration for Playback of EURETINA 2021 Virtual is open until 31 October 2021.

Member Registration Non-Member/ Group Registration